Mycoplasma pneumoniae P1 protein binding protein as well as preparation method and application thereof

By combining fluorescence-activated cell sorting and phage display technologies, the screening cycle of nanobodies was shortened, and the binding strength was enhanced through dimerization modification. This solved the problems of low efficiency and insufficient affinity in the preparation of Mycoplasma pneumoniae P1 protein binding proteins, and enabled highly sensitive diagnostic applications.

CN122127455APending Publication Date: 2026-06-02GUANGZHOU NAT LAB
9 Cites 0 Cited by

Patent Information

Application Number
CN202610069540.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-19
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing technologies for preparing Mycoplasma pneumoniae P1 protein-binding proteins suffer from problems such as long production cycles, low efficiency, and high costs. Furthermore, nanobodies may face challenges due to insufficient affinity in diagnostic applications.

Method used

By combining fluorescence-activated cell sorting technology with phage display technology, the screening cycle is shortened and the screening efficiency of high-affinity nanobodies is improved. At the same time, the binding strength of nanobodies is enhanced through dimerization engineering.

Benefits of technology

It significantly improves the screening efficiency and success rate of nanobodies, provides highly sensitive detection and diagnostic applications, enhances the binding strength to antigens, and solves the problem of insufficient affinity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a mycoplasma pneumoniae P1 protein binding protein as well as a preparation method and application thereof. The mycoplasma pneumoniae P1 protein binding protein comprises an immunoglobulin single variable structural domain, wherein the immunoglobulin single variable structural domain comprises CDR1, CDR2 and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 8. The divalent or multivalent nano antibody prepared by using the mycoplasma pneumoniae P1 protein binding protein can effectively enhance the binding strength of the antigen, and provides a raw material with more excellent performance for developing high-sensitivity detection and diagnosis application.
Need to check novelty before this filing date? Find Prior Art